Abstract

BackgroundGlobally, stomach adenocarcinoma (STAD)’s high morbidity and mortality should arouse our urgent attention. How long can STAD patients survive after surgery and whether novel immunotherapy is effective are questions that our clinicians cannot escape.MethodsVarious R packages, GSEA software, Metascape, STRING, Cytoscape, Venn diagram, TIMER2.0 website, TCGA, and GEO databases were used in our study.ResultsIn the TCGA and GEO, macrophage abundance of STAD tissues was significantly higher than that of adjacent tissues and was an independent prognostic factor, significantly related to the overall survival (OS) of STAD patients. Between the high- and low- macrophage abundance, we conducted differential expression, univariate and multivariate Cox analysis, and obtained 12 candidate genes, and finally constructed a 3-gene signature. Both low macrophage abundance group and group D had higher TMB and PD-L1 expression. Furthermore, top 5 common gene-mutated STAD tissues had lower macrophage abundance. Macrophage abundance and 3 key genes expression were also lower in the Epstein-Barr Virus (EBV) and HM-indel STAD subtypes and significantly correlated with the tumor microenvironment score. The functional enrichment and ssGSEA revealed 2 signatures were similar and closely related to BOQUEST_STEM_CELL_UP, including genes up-regulated in proliferative stromal stem cells. Hsa-miR-335-5p simultaneously regulated 3 key genes and significantly related to the expression of PD-L1, CD8A and PDCD1.Conclusionmacrophage abundance and 3-gene signature could simultaneously predict the OS and immunotherapy efficacy, and both 2 signatures had remarkable similarities. Hsa-miR-335-5p and BOQUEST_STEM_CELL_UP might be novel immunotherapy targets.

Highlights

  • According to the Global Cancer Statistics 2020, the incidence and mortality of stomach adenocarcinoma (STAD) rank fifth and fourth, respectively (Sung et al, 2021)

  • Macrophage abundance was significantly related to the overall survival (OS) of STAD patients

  • Numerous studies have shown that the abundance of tumor infiltrating immune cells are closely related to the prognosis of cancer patients and the efficacy of immunotherapy (Waniczek et al, (STAD) have never been studied

Read more

Summary

Introduction

According to the Global Cancer Statistics 2020, the incidence and mortality of stomach adenocarcinoma (STAD) rank fifth and fourth, respectively (Sung et al, 2021). The curative efficacies of comprehensive clinical treatments including surgery, radiotherapy, and chemotherapy, are not satisfactory (Kang et al, 2012). Targeted therapies, such as the human epidermal growth factor receptor 2 (HER2) monoclonal antibody, can improve the prognosis of advanced STAD. Still, they are only suitable for a small number of STAD patients and face the problem of drug resistance at the same time (Bang et al, 2010). Stomach adenocarcinoma (STAD)’s high morbidity and mortality should arouse our urgent attention. How long can STAD patients survive after surgery and whether novel immunotherapy is effective are questions that our clinicians cannot escape

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call